

Variant: NM_001126112.2(TP53):c.711G>A (p.Met237Ile)

Version: 1.0

CA000349 [↗](#)

142714 (ClinVar) [↗](#)

Gene: TP53 ([HGNC:7157](#))

Condition: Li-Fraumeni syndrome 1 ([MONDO:0007903](#))

Inheritance Mode: Autosomal dominant inheritance

UID: 98acfed4-de66-4a8c-b6ba-bc9a67cd4189

Approved on: 2021-04-20

Published on: 2021-06-16

HGVS expressions

NM_001126112.2:c.711G>A

NM_001126112.2(TP53):c.711G>A (p.Met237Ile)

NC_000017.11:g.7674252C>T

CM000679.2:g.7674252C>T

NC_000017.10:g.7577570C>T

CM000679.1:g.7577570C>T

NC_000017.9:g.7518295C>T

NG_017013.2:g.18299G>A

ENST00000503591.2:c.711G>A

ENST00000508793.6:c.711G>A

ENST00000509690.6:c.315G>A

ENST00000514944.6:c.432G>A

ENST00000604348.6:c.690G>A

ENST00000269305.9:c.711G>A

ENST00000269305.8:c.711G>A

ENST00000359597.8:c.711G>A

ENST00000413465.6:c.711G>A

ENST00000420246.6:c.711G>A

ENST00000445888.6:c.711G>A

ENST00000455263.6:c.711G>A

ENST00000504290.5:c.315G>A

ENST00000504937.5:c.315G>A

ENST00000509690.5:c.315G>A

ENST00000510385.5:c.315G>A

ENST00000514944.5:c.432G>A

ENST00000610292.4:c.594G>A

ENST00000610538.4:c.594G>A

ENST00000610623.4:c.234G>A

ENST00000615910.4:c.678G>A

ENST00000617185.4:c.711G>A

ENST00000618944.4:c.234G>A

ENST00000619186.4:c.234G>A

ENST00000619485.4:c.594G>A

ENST00000620739.4:c.594G>A

ENST00000622645.4:c.594G>A

ENST00000635293.1:c.594G>A

NM_000546.5:c.711G>A

NM_001126113.2:c.711G>A
NM_001126114.2:c.711G>A
NM_001126115.1:c.315G>A
NM_001126116.1:c.315G>A
NM_001126117.1:c.315G>A
NM_001126118.1:c.594G>A
NM_001276695.1:c.594G>A
NM_001276696.1:c.594G>A
NM_001276697.1:c.234G>A
NM_001276698.1:c.234G>A
NM_001276699.1:c.234G>A
NM_001276760.1:c.594G>A
NM_001276761.1:c.594G>A
NM_001276695.2:c.594G>A
NM_001276696.2:c.594G>A
NM_001276697.2:c.234G>A
NM_001276698.2:c.234G>A
NM_001276699.2:c.234G>A
NM_001276760.2:c.594G>A
NM_001276761.2:c.594G>A
NM_000546.6:c.711G>A
NM_001126112.3:c.711G>A
NM_001126113.3:c.711G>A
NM_001126114.3:c.711G>A
NM_001126115.2:c.315G>A
NM_001126116.2:c.315G>A
NM_001126117.2:c.315G>A
NM_001126118.2:c.594G>A
NM_001276695.3:c.594G>A
NM_001276696.3:c.594G>A
NM_001276697.3:c.234G>A
NM_001276698.3:c.234G>A
NM_001276699.3:c.234G>A
NM_001276760.3:c.594G>A
NM_001276761.3:c.594G>A

Pathogenic

Met criteria codes **5**

PP1_Moderate PM6_Supporting PS3
PS4 PM1

Not Met criteria codes **8**

BP4 BS1 BS3 BS2 PP3
PM5 PM2 BA1

Evidence Links **0**

Expert Panel

TP53 VCEP [↗](#)

Criteria Specification Information **!**

[↗](#) **Criteria Specifications for this VCEP**

Evidence submitted by expert panel

TP53 VCEP

This variant has >10 observations as a somatic hotspot variant in tumors (PM1; cancerhotspots.org v(2)). Transactivation assays show a low functioning allele according to Kato, et al. and there is evidence of a dominant negative effect and loss of function according to Giacomelli, et al. (PS3; PMID: 12826609, 30224644). This variant has been reported in 1 proband meeting Classic LFS criteria and 4 probands meeting Chompret criteria (PS4; PMID: 11370630, 25945745, NIH, Invitae, Ambry). This variant was found to co-segregate with disease in multiple affected family members, with 5 or 6 meioses observed (PP1_Moderate; NIH, Invitae). There is one de novo observation in a proband with breast and thyroid cancer in her 30s without parental confirmation (PM6_Supporting; GeneDx). In summary, TP53 c.711G>A (p.Met237Ile) meets criteria to be classified as pathogenic for Li-Fraumeni syndrome. ACMG/AMP criteria applied, as specified by the TP53 Variant Curation Expert Panel: **PM1, PS3, PS4, PP1_Moderate, PM6_Supporting**.

Met criteria codes

| | | |
|-----------------------|---|--|
| PP1_Moderate | ✓ | 6 meioses in across 2 families (NIH, Invitae) |
| PM6_Supporting | ✓ | Assumed de novo in female with breast cancer in 30s (0.5 pts; GeneDx) |
| PS3 | ✓ | Nonfunctional by Kato; LOF by Kotler; LOF+DNE by Giacomelli |
| PS4 | ✓ | NIH: 1 Chompret; 1 classic = 1.5 pts Literature: Chompret = 0.5 pts (PMID:11370630) and Classical = 1 point (PMID: 25945745) Ambry labs: Chompret = 0.5 pts Invitae Lab: Chompret = 0.5 pts 4 total points |
| PM1 | ✓ | 55/64 samples on cancerhotspots.com |

Not Met criteria codes

| | | |
|------------|---|--|
| BP4 | ✗ | aGVGD class C0 (benign) but BayesDel 0.4419>0.16 (path) |
| BS1 | ✗ | Present in 1/17692 East Asian alleles in gnomAD (non-cancer); AF = 0.0057% |
| BS3 | ✗ | No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline |
| BS2 | ✗ | Absent from FLOSSIES. Internal data not received by some ClinVar submitters. |
| PP3 | ✗ | aGVGD class C0 (benign) but BayesDel 0.4419>0.16 (path) |
| PM5 | ✗ | M237T (ID: 481069, VUSx2); M327R (ID: 419524, VUSx1); M237K (ID: 376636, LP somatic only); M237V (ID: 182934, VUSx2) |
| PM2 | ✗ | Present in 1/17692 East Asian alleles in gnomAD (non-cancer); AF = 0.0057% |
| BA1 | ✗ | Present in 1/17692 East Asian alleles in gnomAD (non-cancer); AF = 0.0057% |

Showing 1 to 1 of 1 rows

| |
|--|
| |
|--|

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.